Diffusion Pharmaceuticals Inc. (DFFN) |
| 4.4 0.41 (10.28%) 08-16 16:00 |
| Open: | 4.23 |
| High: | 5.19 |
| Low: | 4.165 |
| Volume: | 349,445 |
| Market Cap: | 9(M) |
| PE Ratio: | -0.62 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
| sell | buy | |||
| Resistance 2: | |
| Resistance 1: | |
| Pivot price: | |
| Support 1: | |
| Support 2: | |
| 52w High: | 14.37 |
| 52w Low: | 4.139999 |
As a biopharmaceutical enterprise, Diffusion Pharmaceuticals Inc. concentrates on pioneering new treatments that bolster the body's efficiency in oxygen distribution. The company's flagship investigational therapy is Trans Sodium Crocetinate, which is formulated to facilitate the spread of oxygen into tissues. This compound is additionally under development for its application in addressing COVID-19. Headquartered in Charlottesville, Virginia, Diffusion Pharmaceuticals Inc. was established in 2001.
Financials
| EPS | |
| Book Value | |
| PEG Ratio | |
| Gross Profit |
| Profit Margin (%) | |
| Operating Margin (%) | |
| Return on Assets (ttm) | |
| Return on Equity (ttm) |
Company news
Sun, 28 Dec 2025
Diffusion Pharmaceuticals (NASDAQ:DFFN) - intelligentinvestor.com.au
Tue, 15 Jul 2025
Tract Bio adds CMO and board members as stem cell pipeline advances | Biotechnology - The Pharma Letter
Tue, 15 Aug 2023
Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma - Yahoo Finance
Wed, 17 Mar 2021
Diffusion Pharmaceuticals (DFFN) Stock Live Price, Chart & News - CoinCodex
Thu, 22 Feb 2018
Diffusion Pharmaceuticals initiates pivotal phase 3 study - Proactive Investors
Fri, 04 Sep 2026
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
